Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**helium + hyperpolarized xenon-129 + nitrogen** is a gas-based MRI contrast agent formulation used to generate inhaled hyperpolarized xenon-129 for pulmonary ventilation imaging. In the provided context, it refers specifically to the isotopically enriched xenon Xe 129 source gas blend used with Polarean's HPX Hyperpolarization System, consisting of helium, nitrogen, and a small fraction of xenon enriched for Xe-129; after hyperpolarization and preparation, the resulting inhaled agent is used as an MRI-visible contrast medium that distributes through ventilated lung regions rather than acting through a conventional pharmacologic receptor target. This formulation is associated with Polarean's XENOVIEW program for evaluation of lung ventilation, including use in disorders such as COPD, idiopathic pulmonary fibrosis, asthma, cystic fibrosis, and perioperative lung assessment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on helium + hyperpolarized xenon-129 + nitrogen.